The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer.
BACKGROUND
Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after surgery (R0 resection) what is associated with an improvement in survival of patients. There is, however, no evidence of survival benefits in patients with R0 resections after prior NACT.


METHODS
We retrospectively reviewed the records of patients who were treated with diagnosis of epithelial ovarian cancer at Institute of Oncology Ljubljana in the years 2005-2007. The differences in the rates of R0 resections, progression free survival (PFS), overall survival (OS) and in five-year and eight-year survival rates between patients treated with NACT and patients who had primary surgery were compared.


RESULTS
Overall 160 patients had stage IIIC epithelial ovarian cancer. Eighty patients had NACT and eighty patients had primary surgery. Patients in NACT group had higher rates of R0 resection (42% vs. 20%; p = 0.011) than patients after primary surgery. PFS was 14.1 months in NACT group and 17.7 months after primary surgery (p = 0.213). OS was 24.8 months in NACT group and 31.6 months after primary surgery (p = 0.012). In patients with R0 resections five-year and eight-year survival rates were 20.6% and 17.6% in NACT group compared to 62.5% and 62.5% after primary surgery (p < 0.0001), respectively.


CONCLUSIONS
Despite higher rates of R0 resections achieved by NACT, survival of patients treated with NACT was inferior to survival of patients who underwent primary surgery. NACT should only be offered to patients with advanced epithelial cancer who are not candidates for primary surgery.
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Erik
E
Škof
Department of Surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Sebastjan
S
Merlo
Department of Surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Gasper
G
Pilko
Division of Gynaecology and Obstetrics, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Borut
B
Kobal
advanced ovarian cancer; neoadjuvant chemotherapy; primary surgery
Gynecol Oncol. 2012 Jan;124(1):1-2
22153125
Gynecol Oncol. 2014 Sep;134(3):462-7
25026637
Gynecol Oncol. 2013 Jan;128(1):6-11
23006973
Int J Gynecol Cancer. 2011 May;21(4):750-5
21543936
Obstet Gynecol. 2006 Jan;107(1):77-85
16394043
Gynecol Oncol. 2001 Sep;82(3):435-41
11520137
N Engl J Med. 2010 Sep 2;363(10):943-53
20818904
Clin Obstet Gynecol. 2012 Mar;55(1):75-95
22343231
Gynecol Oncol. 2012 Jan;124(1):10-4
21917306
J Clin Oncol. 2003 Sep 1;21(17):3194-200
12860964
Gynecol Oncol. 2011 Dec;123(3):461-6
21945309
Gynecol Oncol. 2006 Dec;103(3):1070-6
16875720